Based on its past Ebola vaccine success and adeno associated virus vector technology, Tianjin CanSino Biotechnology Inc. has secured the first clearance in China to start clinical trials for its coronavirus vaccine Ad5-nCoV.
Jointly developed with the Institute of Biotechnologies at the Academy of Military Medical Science (AMMS), it is the first vaccine...







